The effect of MKK4 variants on cancer susceptibility has been assessed in CRC (28, 33), lung cancer (24), acute myeloid leukemia (34), nasopharyngeal carcinoma (35), cervical cancer (36), and breast cancer (37). This evidence concerns the gene MAP2K4 and cancer.